These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

291 related articles for article (PubMed ID: 27902333)

  • 21. Paradoxical role of antibodies in dengue virus infections: considerations for prophylactic vaccine development.
    Acosta EG; Bartenschlager R
    Expert Rev Vaccines; 2016; 15(4):467-82. PubMed ID: 26577689
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Dengue Virus Infection with Highly Neutralizing Levels of Cross-Reactive Antibodies Causes Acute Lethal Small Intestinal Pathology without a High Level of Viremia in Mice.
    Watanabe S; Chan KW; Wang J; Rivino L; Lok SM; Vasudevan SG
    J Virol; 2015 Jun; 89(11):5847-61. PubMed ID: 25787279
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Evaluation by flow cytometry of antibody-dependent enhancement (ADE) of dengue infection by sera from Thai children immunized with a live-attenuated tetravalent dengue vaccine.
    Guy B; Chanthavanich P; Gimenez S; Sirivichayakul C; Sabchareon A; Begue S; Yoksan S; Luxemburger C; Lang J
    Vaccine; 2004 Sep; 22(27-28):3563-74. PubMed ID: 15315835
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Lethal antibody enhancement of dengue disease in mice is prevented by Fc modification.
    Balsitis SJ; Williams KL; Lachica R; Flores D; Kyle JL; Mehlhop E; Johnson S; Diamond MS; Beatty PR; Harris E
    PLoS Pathog; 2010 Feb; 6(2):e1000790. PubMed ID: 20168989
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Characterization of a potent and highly unusual minimally enhancing antibody directed against dengue virus.
    Renner M; Flanagan A; Dejnirattisai W; Puttikhunt C; Kasinrerk W; Supasa P; Wongwiwat W; Chawansuntati K; Duangchinda T; Cowper A; Midgley CM; Malasit P; Huiskonen JT; Mongkolsapaya J; Screaton GR; Grimes JM
    Nat Immunol; 2018 Nov; 19(11):1248-1256. PubMed ID: 30323338
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Dengue virus isolation relying on antibody-dependent enhancement mechanism using FcγR-expressing BHK cells and a monoclonal antibody with infection-enhancing capacity.
    Moi ML; Lim CK; Tajima S; Kotaki A; Saijo M; Takasaki T; Kurane I
    J Clin Virol; 2011 Nov; 52(3):225-30. PubMed ID: 21824813
    [TBL] [Abstract][Full Text] [Related]  

  • 27. An affinity-matured human monoclonal antibody targeting fusion loop epitope of dengue virus with in vivo therapeutic potency.
    Kotaki T; Kurosu T; Grinyo-Escuer A; Davidson E; Churrotin S; Okabayashi T; Puiprom O; Mulyatno KC; Sucipto TH; Doranz BJ; Ono KI; Soegijanto S; Kameoka M
    Sci Rep; 2021 Jun; 11(1):12987. PubMed ID: 34155267
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Dengue virus infection-enhancing activity of undiluted sera obtained from patients with secondary dengue virus infection.
    Moi ML; Takasaki T; Saijo M; Kurane I
    Trans R Soc Trop Med Hyg; 2013 Jan; 107(1):51-8. PubMed ID: 23296697
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A bispecific antibody effectively neutralizes all four serotypes of dengue virus by simultaneous blocking virus attachment and fusion.
    Shi X; Deng Y; Wang H; Ji G; Tan W; Jiang T; Li X; Zhao H; Xia T; Meng Y; Wang C; Yu X; Yang Y; Li B; Qin ED; Dai J; Qin CF; Guo Y
    MAbs; 2016; 8(3):574-84. PubMed ID: 26905804
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A human bispecific neutralization antibody against four serotypes of dengue virus.
    Wang R; Lu J; Chen L; Yu Y; Yang Z
    Virology; 2021 Jun; 558():49-56. PubMed ID: 33721729
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Defining New Therapeutics Using a More Immunocompetent Mouse Model of Antibody-Enhanced Dengue Virus Infection.
    Pinto AK; Brien JD; Lam CY; Johnson S; Chiang C; Hiscott J; Sarathy VV; Barrett AD; Shresta S; Diamond MS
    mBio; 2015 Sep; 6(5):e01316-15. PubMed ID: 26374123
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Complexity of Neutralizing Antibodies against Multiple Dengue Virus Serotypes after Heterotypic Immunization and Secondary Infection Revealed by In-Depth Analysis of Cross-Reactive Antibodies.
    Tsai WY; Durbin A; Tsai JJ; Hsieh SC; Whitehead S; Wang WK
    J Virol; 2015 Jul; 89(14):7348-62. PubMed ID: 25972550
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Cross-reacting antibodies enhance dengue virus infection in humans.
    Dejnirattisai W; Jumnainsong A; Onsirisakul N; Fitton P; Vasanawathana S; Limpitikul W; Puttikhunt C; Edwards C; Duangchinda T; Supasa S; Chawansuntati K; Malasit P; Mongkolsapaya J; Screaton G
    Science; 2010 May; 328(5979):745-8. PubMed ID: 20448183
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Low levels of antibody-dependent enhancement in vitro using viruses and plasma from dengue patients.
    Chaichana P; Okabayashi T; Puiprom O; Sasayama M; Sasaki T; Yamashita A; Ramasoota P; Kurosu T; Ikuta K
    PLoS One; 2014; 9(3):e92173. PubMed ID: 24642752
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Zika convalescent macaques display delayed induction of anamnestic cross-neutralizing antibody responses after dengue infection.
    Valiant WG; Huang YS; Vanlandingham DL; Higgs S; Lewis MG; Mattapallil JJ
    Emerg Microbes Infect; 2018 Jul; 7(1):130. PubMed ID: 30006514
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Japanese encephalitis vaccine-facilitated dengue virus infection-enhancement antibody in adults.
    Saito Y; Moi ML; Takeshita N; Lim CK; Shiba H; Hosono K; Saijo M; Kurane I; Takasaki T
    BMC Infect Dis; 2016 Oct; 16(1):578. PubMed ID: 27756212
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Dengue immune sera enhance Zika virus infection in human peripheral blood monocytes through Fc gamma receptors.
    Li M; Zhao L; Zhang C; Wang X; Hong W; Sun J; Liu R; Yu L; Wang J; Zhang F; Jin X
    PLoS One; 2018; 13(7):e0200478. PubMed ID: 30044839
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Neuraminidase augments Fc gamma receptor II-mediated antibody-dependent enhancement of dengue virus infection.
    Mady BJ; Kurane I; Erbe DV; Fanger MW; Ennis FA
    J Gen Virol; 1993 May; 74 ( Pt 5)():839-44. PubMed ID: 8492089
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Dengue Virus and Zika Virus Serological Cross-reactivity and Their Impact on Pathogenesis in Mice.
    Watanabe S; Tan NWW; Chan KWK; Vasudevan SG
    J Infect Dis; 2019 Jan; 219(2):223-233. PubMed ID: 30085051
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Plant-Produced Anti-Zika Virus Monoclonal Antibody Glycovariant Exhibits Abrogated Antibody-Dependent Enhancement of Infection.
    Yang M; Sun H; Lai H; Neupane B; Bai F; Steinkellner H; Chen Q
    Vaccines (Basel); 2023 Mar; 11(4):. PubMed ID: 37112665
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.